Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

HM15211

Stage Phase 1Stale

Sponsor Hanmi Pharmaceutical Company Limited

Route injection

Sources

registry, as of 2025-01-27Stale

https://clinicaltrials.gov/study/NCT03744182

A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD. Overall status COMPLETED. Phases PHASE1. Lead sponsor Hanmi Pharmaceutical Company Limited. Enrollment 66. Conditions NAFLD. This study is a phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HM15211 in obese subjects with NAFLD deaths 0.01 mg/kg HM15211 0 nausea 0.01 mg/kg HM15211 1 vomiting 0.01 mg/kg HM15211 1 deaths 0.02 mg/kg HM15211 0 nausea 0.02 mg/kg HM15211 1 vomiting 0.02 mg/kg HM15211 0 deaths 0.04 mg/kg HM15211 0 nausea 0.04 mg/kg HM15211 2 vomiting 0.04 mg/kg HM15211 0 deaths 0.06 mg/kg HM15211 0 nausea 0.06 mg/kg HM15211 3 vomiting 0.06 mg/kg HM15211 1

ClinicalTrials.gov NCT03744182 protocol and results modules

registry, as of 2025-02-06Stale

https://clinicaltrials.gov/study/NCT03374241

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide). Overall status COMPLETED. Phases PHASE1. Lead sponsor Hanmi Pharmaceutical Company Limited. Enrollment 41. Conditions Obesity. Single ascending dose of HM15211 in healthy obese subjects. deaths Cohort 1 Active 0 deaths Cohort 2 Active 0 deaths Cohort 3 Active 0 deaths Cohort 4 Active 0 deaths Cohort 5 Active 0

ClinicalTrials.gov NCT03374241 protocol and results modules

Studies

A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD

Registry NCT03744182

Phase Phase 1

Status Completed

Enrollment 66

Start 2018-11-01

Primary completion 2020-03-18

Study completion 2020-03-18

HM15211

Comparator placebo

Population NAFLD

deaths

participants with nausea, 1 participantsStale

participants with vomiting, 1 participantsStale

Placebo

Population NAFLD

deaths

participants with nausea, 1 participantsStale

participants with vomiting, 1 participantsStale

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)

Registry NCT03374241

Phase Phase 1

Status Completed

Enrollment 41

Start 2018-04-04

Primary completion 2018-09-14

Study completion 2018-09-14

Cohort 1

Population Obesity

deaths

Cohort 2

Population Obesity

deaths

Cohort 3

Population Obesity

deaths

Cohort 4

Population Obesity

deaths

Cohort 5

Population Obesity

deaths